TIL(TIL)
TIL
ANALYST COVERAGE7 analysts
HOLD
▼ -13.9%downside to target
Key MetricsTTM
Market Cap$55.00M
Revenue TTM$0.00
Net Income TTM-$47.38M
Free Cash Flow-$33.76M
Gross Margin0.0%
Operating Margin0.0%
Net Margin0.0%
Return on Equity-39.8%
Return on Assets-23.6%
Debt / Equity0.00
Current Ratio39.87
EPS TTM$-6.99
PRICE
Prev Close
8.12
Open
8.10
Day Range8.07 – 8.21
8.07
8.21
52W Range5.67 – 42.79
5.67
42.79
7% of range
VOLUME & SIZE
Avg Volume
29.9K
FUNDAMENTALS
P/E Ratio
-1.2x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
1.76
High vol
TECHNICAL
RSI (14)
42
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 23
DEx-Dividend
In 90 days
Aug 20
PDividend Pay
In 131 days
Sep 30
TIL News
About
Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies for the treatment of patients with cancer.
Industry
Research and Development in Biotechnology
Website
Qiying LuChief Medical Officer & Senior Vice President of China
Sandeep LaumasChief Financial Officer & Chief Business Officer
Bronson CrouchChairman & Chief Executive Officer
James FreedmanChief Medical Officer